{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:12:35Z","timestamp":1789456355681,"version":"build-2803163510"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Drug repurposing represents a cost-effective and time-efficient strategy to expand therapeutic treatment options. Colchicine, traditionally used for gout and familial Mediterranean fever, has gained attention as a candidate for diverse conditions. This study aimed to provide a comprehensive and critical overview of clinical trials on colchicine repurposing, with particular focus on reliability, significance, and safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured search of clinicaltrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) was completed on July 07 2026. Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guideline, PubMed and Scopus were searched using the term \u201ccolchicine AND repurposing\u201d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>40 clinical trials were included. Nine addressed COVID-19, 26 cardiovascular conditions or related interventions, and five with other indications. Evidence in COVID-19 was inconsistent. Cardiovascular evidence was strong for chronic coronary artery disease and prevention after myocardial infarction. Findings in acute coronary syndromes, percutaneous coronary intervention, surgery and heart failure were mixed and often limited to surrogate endpoints. Other indications did not observe a significant benefit. Most frequent adverse effects were gastrointestinal, particularly diarrhoea. Increased non-cardiovascular mortality in individual trials highlights toxicity potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence most consistently supports colchicine for secondary cardiovascular prevention in established coronary disease. No reliable evidence is found for benefit across broader cardiovascular conditions, COVID-19 or other indications. A narrow therapeutic index and high drug-interaction potential necessitate careful patient selection and monitoring. Well-powered and methodologically robust clinical trials are required to investigate and confirm potential benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04149-w","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T01:44:21Z","timestamp":1787190261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing of colchicine: critical examination of clinical trials and scoping review"],"prefix":"10.1007","volume":"82","author":[{"given":"Lilly Josephine","family":"Bindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"4149_CR1","doi-asserted-by":"crossref","unstructured":"Adam GP, Springs S, Trikalinos T et al (2018) Does information from ClinicalTrials.gov increase transparency and reduce bias? Results from a five-report case series. Syst Rev 7:59. 10.1186\/s13643-018-0726-5","DOI":"10.1186\/s13643-018-0726-5"},{"issue":"1","key":"4149_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12872-021-02393-9","volume":"21","author":"M Akrami","year":"2021","unstructured":"Akrami M, Izadpanah P, Bazrafshan M, Hatamipour U, Nouraein N, Drissi HB, Manafi A (2021) Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc Disord 21(1):583. https:\/\/doi.org\/10.1186\/s12872-021-02393-9","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"4149_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s12903-023-03335-x","volume":"23","author":"S Alsahaf","year":"2023","unstructured":"Alsahaf S, Alkurdi KA, Challacombe SJ, Tappuni AR (2023) Topical betamethasone and systemic colchicine for treatment of recurrent aphthous stomatitis: a randomised clinical trial. BMC Oral Health 23(1):709. https:\/\/doi.org\/10.1186\/s12903-023-03335-x","journal-title":"BMC Oral Health"},{"issue":"7","key":"4149_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/metabo15070424","volume":"15","author":"A Alunno","year":"2025","unstructured":"Alunno A, Carubbi F, Ferri C (2025) Uric acid, colchicine and chronic inflammatory diseases: a cardiovascular perspective. Metabolites 15(7):424. https:\/\/doi.org\/10.3390\/metabo15070424","journal-title":"Metabolites"},{"issue":"4","key":"4149_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040783","volume":"10","author":"F Atzeni","year":"2021","unstructured":"Atzeni F, Masala IF, Rodr\u00edguez-Carrio J, R\u00edos-Garc\u00e9s R, Gerratana E, La Corte L, Giallanza M, Nucera V, Riva A, Espinosa G, Cervera R (2021) The rheumatology drugs for COVID-19 management: which and when? J Clin Med 10(4):783. https:\/\/doi.org\/10.3390\/jcm10040783","journal-title":"J Clin Med"},{"key":"4149_CR6","unstructured":"Australian New Zealand Clinical Trials Registry (ANZCTR) (2026) Trial Search. https:\/\/www.anzctr.org.au\/Default.aspx. Accessed 31 July 2026"},{"key":"4149_CR7","doi-asserted-by":"publisher","unstructured":"Banifatemeh SA, Hajahmadi M, Nasiripour S, Farasatinasab M, Deihim N et al (2025). The positive effects of colchicine against inflammatory cytokines in patients after acute mi: a randomized clinical trial study. Zahedan J Res Med Sci 27(2):e160796. https:\/\/doi.org\/10.5812\/zjrms-160796","DOI":"10.5812\/zjrms-160796"},{"key":"4149_CR8","doi-asserted-by":"publisher","unstructured":"Beck RW (2006) Sample size for a clinical trial: why do some trials need only 100 patients and others 1000 patients or more? Ophthalmology 113(5):721\u2013722. https:\/\/doi.org\/10.1016\/j.ophtha.2006.02.008","DOI":"10.1016\/j.ophtha.2006.02.008"},{"issue":"5","key":"4149_CR9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ejcts\/ezx422","volume":"53","author":"A Bessissow","year":"2018","unstructured":"Bessissow A, Agzarian J, Shargall Y, Srinathan S, Neary J, Tandon V, Finley C, Healey JS, Conen D, Rodseth R, Pettit S, Dechert W, Regalado O, Ramasundarahettige C, Alshalash S, Devereaux PJ (2018) Colchicine for Prevention of Perioperative Atrial Fibrillation in patients undergoing lung resection surgery: a pilot randomized controlled study. Eur J Cardiothorac Surg 53(5):945\u2013951. https:\/\/doi.org\/10.1093\/ejcts\/ezx422","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9","key":"4149_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11886-021-01560-w","volume":"23","author":"N Bouabdallaoui","year":"2021","unstructured":"Bouabdallaoui N, Tardif JC (2021) Colchicine in the management of acute and chronic coronary artery disease. Curr Cardiol Rep 23(9):120. https:\/\/doi.org\/10.1007\/s11886-021-01560-w","journal-title":"Curr Cardiol Rep"},{"key":"4149_CR11","doi-asserted-by":"publisher","unstructured":"Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Lopez-Sendon J, Gamra H, Kiwan GS, Blondeau L, Orfanos A, Ibrahim R, Gr\u00e9goire JC, Dub\u00e9 MP, Samuel M, Morel O, Lim P, Bertrand OF, \u2026 Roubille F (2020) Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J 41(42):4092\u20134099. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa659","DOI":"10.1093\/eurheartj\/ehaa659"},{"key":"4149_CR12","unstructured":"Bruckner T (2020) Why is uploading clinical trial results onto trial registries so important? TranspariMED. Last updated: January 27 2020. Last accessed: August 31 2025. https:\/\/www.transparimed.org\/single-post\/2019\/04\/24\/why-is-uploading-clinical-results-onto-trial-registries-so-important"},{"issue":"12","key":"4149_CR13","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1111\/1462-2920.15828","volume":"23","author":"H Br\u00fcssow","year":"2021","unstructured":"Br\u00fcssow H (2021) Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. Environ Microbiol 23(12):7257\u20137270. https:\/\/doi.org\/10.1111\/1462-2920.15828","journal-title":"Environ Microbiol"},{"key":"4149_CR14","doi-asserted-by":"publisher","unstructured":"Buckley LF, Libby P (2024) Colchicine\u2019s role in cardiovascular disease management. ATVB 44(5). https:\/\/doi.org\/10.1161\/ATVBAHA.124.319851","DOI":"10.1161\/ATVBAHA.124.319851"},{"issue":"11","key":"4149_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/metabo14110629","volume":"14","author":"FV Bulh\u00f5es","year":"2024","unstructured":"Bulh\u00f5es FV, Assis GE, Caz\u00e9 AB, Barros-Pereira JP, Laguna GGC, Improta-Caria AC, Aras-J\u00fanior R (2024) The action of colchicine in patients with metabolic syndrome and obesity: perspectives and challenges. Metabolites 14(11):629. https:\/\/doi.org\/10.3390\/metabo14110629","journal-title":"Metabolites"},{"key":"4149_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40814-018-0324-2","volume":"4","author":"MJ Campbell","year":"2018","unstructured":"Campbell MJ, Lancaster GA, Eldridge SM (2018) A randomised controlled trial is not a pilot trial simply because it uses a surrogate endpoint. Pilot Feasibility Stud 4:130. https:\/\/doi.org\/10.1186\/s40814-018-0324-2","journal-title":"Pilot Feasibility Stud"},{"issue":"3","key":"4149_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/ejcts\/ezab355","volume":"61","author":"JY Cao","year":"2022","unstructured":"Cao JY, Marathe SP, Zannino D, Celermajer DS, Justo RN, Alphonso N, d\u2019Udekem Y, Winlaw DS (2022) Fontan operation at less than 3 years of age is not a risk factor for long-term failure. Eur J Cardiothorac Surg 61(3):497\u2013504. https:\/\/doi.org\/10.1093\/ejcts\/ezab355","journal-title":"Eur J Cardiothorac Surg"},{"issue":"8","key":"4149_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/fca-2020-0206","volume":"18","author":"M Casula","year":"2022","unstructured":"Casula M, Andreis A, Avondo S, Vaira MP, Imazio M (2022) Colchicine for cardiovascular medicine: a systematic review and meta-analysis. Future Cardiol 18(8):647\u2013659. https:\/\/doi.org\/10.2217\/fca-2020-0206","journal-title":"Future Cardiol"},{"key":"4149_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1046406","volume":"13","author":"L Chaffey","year":"2022","unstructured":"Chaffey L, Roberti A, Greaves DR (2022) Drug repurposing in cardiovascular inflammation: successes, failures, and future opportunities. Front Pharmacol 13:1046406. https:\/\/doi.org\/10.3389\/fphar.2022.1046406","journal-title":"Front Pharmacol"},{"key":"4149_CR20","unstructured":"ChiCTR. (2026). Chinese Clinical Trial Registry. Primary Registry of WHO International Clnical Trials Registry Platform, 2026. Last accessed: July 06 2026. https:\/\/www.chictr.org.cn\/indexEN.html"},{"issue":"2","key":"4149_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s43441-019-00073-7","volume":"54","author":"JB Christian","year":"2020","unstructured":"Christian JB, Brouwer ES, Girman CJ, Bennett D, Davis KJ, Dreyer NA (2020) Masking in pragmatic trials: who, what, and when to blind. Ther Innov Regul Sci 54(2):431\u2013436. https:\/\/doi.org\/10.1007\/s43441-019-00073-7","journal-title":"Ther Innov Regul Sci"},{"key":"4149_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.carrev.2021.09.006","volume":"39","author":"J Cole","year":"2022","unstructured":"Cole J, Htun N, Lew R, Freilich M, Quinn S, Layland J (2022) Colchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention (COPE-PCI): a descriptive cytokine pilot sub-study. Cardiovasc Revasc Med 39:84\u201389. https:\/\/doi.org\/10.1016\/j.carrev.2021.09.006","journal-title":"Cardiovasc Revasc Med"},{"issue":"4","key":"4149_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14779072.2026.2652411","volume":"24","author":"WA Courtney","year":"2026","unstructured":"Courtney WA, Walker J, Dorai-Raj A, Arnous S, O\u2019Connor CT, Playford D, Ihdayhid A, Schultz CJ, Hillis GS, Kiernan TJ (2026) Medical therapies to prevent the development and progression of calcific aortic valve stenosis: a contemporary review. Expert Rev Cardiovasc Ther 24(4):339\u2013351. https:\/\/doi.org\/10.1080\/14779072.2026.2652411","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"24","key":"4149_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijans.2026.101009","volume":"2026","author":"V Damanpak-Moghadam","year":"2026","unstructured":"Damanpak-Moghadam V, Ghorbani M, Ahmadi A, Heidarifar R (2026) Investigating the effectiveness of colchicine tablets on the outcomes of mechanically ventilated patients with COVID-19: a randomized clinical trial. Int J Afr Nurs Sci 2026(24):101009. https:\/\/doi.org\/10.1016\/j.ijans.2026.101009","journal-title":"Int J Afr Nurs Sci"},{"issue":"10","key":"4149_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20155","volume":"9","author":"MI Danjuma","year":"2023","unstructured":"Danjuma MI, Sayed R, Aboughalia M, Hassona A, Elsayed BS, Elshafei M, Elzouki A (2023) Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses. Heliyon 9(10):e20155. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20155","journal-title":"Heliyon"},{"issue":"2","key":"4149_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.15896","volume":"178","author":"B Dasgeb","year":"2018","unstructured":"Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL (2018) Colchicine: an ancient drug with novel applications. Br J Dermatol 178(2):350\u2013356. https:\/\/doi.org\/10.1111\/bjd.15896","journal-title":"Br J Dermatol"},{"key":"4149_CR27","doi-asserted-by":"publisher","first-page":"17887","DOI":"10.1038\/s41598-023-44264-7","volume":"13","author":"MC De Rosa","year":"2023","unstructured":"De Rosa MC, Purohit R, Garc\u00eda-Sosa AT (2023) Drug repurposing: a nexus of innovation, science, and potential. Sci Rep 13:17887. https:\/\/doi.org\/10.1038\/s41598-023-44264-7","journal-title":"Sci Rep"},{"key":"4149_CR28","doi-asserted-by":"publisher","unstructured":"Demidowich AP, Levine JA, Onyekaba GI, Khan SM, Chen KY, Brady SM, Broadney MM, Yanovski JA (2019) Effects of colchicine in adults with metabolic syndrome: a pilot randomized controlled trial. Diabetes Obes Metab 21(7):1642\u20131651. https:\/\/doi.org\/10.1111\/dom.13702","DOI":"10.1111\/dom.13702"},{"key":"4149_CR29","doi-asserted-by":"publisher","unstructured":"Demidowich AP, Levine JA, Apps R et al (2020) Colchicine\u2019s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial. Int J Obes 44:1793\u20131799. https:\/\/doi.org\/10.1038\/s41366-020-0598-3","DOI":"10.1038\/s41366-020-0598-3"},{"key":"4149_CR30","doi-asserted-by":"publisher","unstructured":"Ding H, Cheng CK, Jiang M, Cheng X, Huang Y (2026) Colchicine in cardiovascular medicine: current perspectives on mechanisms and clinical therapeutics. Pharmacol Ther 285:109053. https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109053","DOI":"10.1016\/j.pharmthera.2026.109053"},{"issue":"1","key":"4149_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00431-025-06726-0","volume":"185","author":"RF Dipasquale","year":"2026","unstructured":"Dipasquale RF, Sinopoli P, Mendicino A, Gallizzi R (2026) Colchicine prophylaxis in pediatric PFAPA: a systematic review. Eur J Pediatr 185(1):57. https:\/\/doi.org\/10.1007\/s00431-025-06726-0","journal-title":"Eur J Pediatr"},{"key":"4149_CR32","doi-asserted-by":"publisher","unstructured":"Dudam R, Dekate P (2020) Old drug, new trick: colchicine for cardiovascular diseases. J R Coll Physicians Edinb 50(1):49\u201350. https:\/\/doi.org\/10.4997\/JRCPE.2020.113","DOI":"10.4997\/JRCPE.2020.113"},{"issue":"9","key":"4149_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13645","volume":"51","author":"MN Elshafei","year":"2021","unstructured":"Elshafei MN, El-Bardissy A, Khalil A, Danjuma M, Mubasher M, Abubeker IY, Mohamed MFH (2021) Colchicine use might be associated with lower mortality in COVID-19 patients: a meta-analysis. Eur J Clin Invest 51(9):e13645. https:\/\/doi.org\/10.1111\/eci.13645","journal-title":"Eur J Clin Invest"},{"key":"4149_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12890-024-03001-0","volume":"24","author":"K Elshiwy","year":"2024","unstructured":"Elshiwy K, Amin GEED, Farres MN et al (2024) The role of colchicine in the management of COVID-19: a Meta-analysis. BMC Pulm Med 24:190. https:\/\/doi.org\/10.1186\/s12890-024-03001-0","journal-title":"BMC Pulm Med"},{"key":"4149_CR35","unstructured":"Erickson M (2020) Many early COVID-19 studies have low-quality design, risk low-value evidence, research finds. Standford Medicine. Last updated: July 28 2020. Last accessed: September 06 2025."},{"key":"4149_CR36","unstructured":"European Medicines Agency (EMA) (2025) ICH E6 (R3) Guideline for good clinical practive (GCP). Reference Number: EMA\/CHMP\/ICH\/135\/1995. Last updated: July 23 2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e6-r3-guideline-good-clinical-practice-gcp-step-5_en.pdf. Accessed 31 July 2026"},{"key":"4149_CR37","doi-asserted-by":"publisher","unstructured":"Evans K, Seifert R (2025) Repurposing of NKA inhibitors (\u2018cardiac glycosides\u2019): a critical analysis. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04443-x","DOI":"10.1007\/s00210-025-04443-x"},{"issue":"15","key":"4149_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157652","volume":"26","author":"M Ezzo","year":"2025","unstructured":"Ezzo M, Etienne-Manneville S (2025) Microtubule-targeting agents: advances in tubulin binding and small molecule therapy for gliomas and neurodegenerative diseases. Int J Mol Sci 26(15):7652. https:\/\/doi.org\/10.3390\/ijms26157652","journal-title":"Int J Mol Sci"},{"key":"4149_CR39","doi-asserted-by":"publisher","first-page":"5918393","DOI":"10.1155\/2016\/5918393","volume":"2016","author":"G Faghihi","year":"2016","unstructured":"Faghihi G, Elahipoor A, Iraji F, Behfar S, Abtahi-Naeini B (2016) Topical colchicine gel versus diclofenac sodium gel for the treatment of actinic keratoses: a randomized. Double-Blind Study Adv Med 2016:5918393. https:\/\/doi.org\/10.1155\/2016\/5918393","journal-title":"Double-Blind Study Adv Med"},{"key":"4149_CR40","doi-asserted-by":"publisher","unstructured":"Farzaneh AH, Abbaspour H, Habibi V, Sadraei SJ, Darayi M, Moradi S, Nataj AH (2026) Short-term, weight-adjusted colchicine to prevent post-cabg arrhythmias: a randomized, double-blind, controlled trial. PACE. https:\/\/doi.org\/10.1111\/pace.70278","DOI":"10.1111\/pace.70278"},{"issue":"12","key":"4149_CR41","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/biom14121515","volume":"14","author":"L Franceschin","year":"2024","unstructured":"Franceschin L, Guidotti A, Mazzetto R, Tartaglia J, Ciolfi C, Alaibac M, Sernicola A (2024) Repurposing historic drugs for neutrophil-mediated inflammation in skin disorders. Biomolecules 14(12):1515. https:\/\/doi.org\/10.3390\/biom14121515","journal-title":"Biomolecules"},{"key":"4149_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113894","volume":"177","author":"P Gelosa","year":"2020","unstructured":"Gelosa P, Castiglioni L, Camera M, Sironi L (2020) Drug repurposing in cardiovascular diseases: opportunity or hopeless dream? Biochem Pharmacol 177:113894. https:\/\/doi.org\/10.1016\/j.bcp.2020.113894","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"4149_CR43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60364","volume":"16","author":"E Gertner","year":"2024","unstructured":"Gertner E, Schullo-Feulner A, Knutson A, Chrenka E, O\u2019Brien M, Behrendt C, Johnson J, Delaney D (2024) Colchicine and\/or naltrexone for hospitalized COVID-19 patients not requiring high levels of ventilatory support (COLTREXONE): a prospective, randomized open-label trial. Cureus 16(5):e60364. https:\/\/doi.org\/10.7759\/cureus.60364","journal-title":"Cureus"},{"issue":"39","key":"4149_CR44","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.2174\/1381612827666211210142352","volume":"28","author":"HS Ghaith","year":"2022","unstructured":"Ghaith HS, Gabra MD, Nafady MH, Elshawah HE, Negida A, Mushtaq G, Kamal MA (2022) A review of the rational and current evidence on colchicine for COVID-19. Curr Pharm Des 28(39):3194\u20133201. https:\/\/doi.org\/10.2174\/1381612827666211210142352","journal-title":"Curr Pharm Des"},{"issue":"6","key":"4149_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S104795112200186X","volume":"33","author":"SA Goldstein","year":"2022","unstructured":"Goldstein SA, Nolan K, Marchetti K, Stoscup JK, Clewis H, Jarvis K, Halligan NLN, Dahmer MK, Schumacher KR, Rocchini A (2022) Colchicine in post-operative Fontan patients. Cardiol Young 33(6):1\u20137. https:\/\/doi.org\/10.1017\/S104795112200186X","journal-title":"Cardiol Young"},{"issue":"1","key":"4149_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4103\/2229-3485.106383","volume":"4","author":"U Gupta","year":"2013","unstructured":"Gupta U, Verma M (2013) Placebo in clinical trials. Perspect Clin Res 4(1):49\u201352. https:\/\/doi.org\/10.4103\/2229-3485.106383","journal-title":"Perspect Clin Res"},{"key":"4149_CR47","doi-asserted-by":"publisher","unstructured":"Handari SD, Rohman MS, Sargowo D, Aulanni\u2019am, Qosimah D, Lestari B, Nugraha RA (2025) Targeting inflammation with Galectin-3 and PIIINP modulation among st-segment elevation acute coronary syndrome patients underwent delayed percutaneous coronary intervention. Biomedicines 13(2): 259. https:\/\/doi.org\/10.3390\/biomedicines13020259","DOI":"10.3390\/biomedicines13020259"},{"issue":"3","key":"4149_CR48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40264-022-01265-1","volume":"46","author":"PD Hansten","year":"2023","unstructured":"Hansten PD, Tan MS, Horn JR, Gomez-Lumbreras A, Villa-Zapata L, Boyce RD, Subbian V, Romero A, Gephart S, Malone DC (2023) Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Drug Saf 46(3):223\u2013242. https:\/\/doi.org\/10.1007\/s40264-022-01265-1","journal-title":"Drug Saf"},{"issue":"3","key":"4149_CR49","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/2772434418666230914113010","volume":"19","author":"S Hejazi","year":"2024","unstructured":"Hejazi S, Jahani Z, Elyasi S, Salarbashi D, Kabiri M (2024) The efficacy of colchicine as an adjunct therapy in non-hospitalized COVID-19 patients: a randomized placebo-controlled trial. Recent Adv Antiinfect Drug Discov 19(3):254\u2013263. https:\/\/doi.org\/10.2174\/2772434418666230914113010","journal-title":"Recent Adv Antiinfect Drug Discov"},{"key":"4149_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","volume":"215","author":"G Hillis","year":"2019","unstructured":"Hillis G, Patel S, Schultz C, Kurup R, Bowman M, Soh L, Hennessy T (2019) The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 215:62\u201369. https:\/\/doi.org\/10.1016\/j.ahj.2019.06.003","journal-title":"Am Heart J"},{"issue":"4","key":"4149_CR51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/FJC.0000000000001317","volume":"80","author":"SH Hosseini","year":"2022","unstructured":"Hosseini SH, Talasaz AH, Alidoosti M, Tajdini M, Van Tassell BW, Etesamifard N, Kakavand H, Jalali A, Aghakouchakzadeh M, Gheymati A, Sadeghian M, Jenab Y (2022) Preprocedural colchicine in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a randomized controlled trial (PodCAST-PCI). J Cardiovasc Pharmacol 80(4):592\u2013599. https:\/\/doi.org\/10.1097\/FJC.0000000000001317","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"4149_CR52","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s42399-020-00485-9","volume":"2","author":"MS Hossen","year":"2020","unstructured":"Hossen MS, Barek MA, Jahan N, Safiqul Islam M (2020) A review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med 2(10):1777\u20131789. https:\/\/doi.org\/10.1007\/s42399-020-00485-9","journal-title":"SN Compr Clin Med"},{"issue":"6","key":"4149_CR53","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.ahj.2015.09.020","volume":"170","author":"A Izadi Amoli","year":"2015","unstructured":"Izadi Amoli A, Bozorgi A, HajHossein Talasaz A, Salehi Omran A, Mortazavi SH, Jalali A, Nasirpour S, Jenab Y (2015) Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery: a randomized, placebo-controlled trial. Am Heart J 170(6):1195\u20131201. https:\/\/doi.org\/10.1016\/j.ahj.2015.09.020","journal-title":"Am Heart J"},{"issue":"sup1","key":"4149_CR54","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1080\/15374416.2017.1342547","volume":"48","author":"L Jones","year":"2019","unstructured":"Jones L, Black SR, Arnold LE, Fristad MA (2019) Not all masks are created equal: masking success in clinical trials of children and adolescents. J Clin Child Adolesc Psychol 48(sup1):S227\u2013S233. https:\/\/doi.org\/10.1080\/15374416.2017.1342547","journal-title":"J Clin Child Adolesc Psychol"},{"key":"4149_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/nature.2013.14286","author":"N Jones","year":"2013","unstructured":"Jones N (2013) Half of US clinical trials go unpublished. Nature. https:\/\/doi.org\/10.1038\/nature.2013.14286","journal-title":"Nature"},{"issue":"7303","key":"4149_CR56","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","volume":"323","author":"P J\u00fcni","year":"2001","unstructured":"J\u00fcni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ (Clinical research ed) 323(7303):42\u201346. https:\/\/doi.org\/10.1136\/bmj.323.7303.42","journal-title":"BMJ (Clinical research ed)"},{"issue":"2","key":"4149_CR57","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/ijms23020804","volume":"23","author":"TW Kao","year":"2022","unstructured":"Kao TW, Huang CC (2022) Inflammatory burden and immunomodulative therapeutics of cardiovascular diseases. Int J Mol Sci 23(2):804. https:\/\/doi.org\/10.3390\/ijms23020804","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4149_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/10815589221141815","volume":"71","author":"H Kasiri","year":"2023","unstructured":"Kasiri H, Ghazaiean M, Rouhani N, Naderi-Behdani F, Ghazaeian M, Ghodssi-Ghassemabadi R (2023) The effects of colchicine on hospitalized COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial. J Investig Med 71(2):124\u2013131. https:\/\/doi.org\/10.1177\/10815589221141815","journal-title":"J Investig Med"},{"issue":"8","key":"4149_CR59","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1440-1797.2010.01432.x","volume":"15","author":"PJ Kelly","year":"2010","unstructured":"Kelly PJ, Webster AC, Craig JC (2010) How many patients do we need for a clinical trial? Demystifying sample size calculations. Nephrology (Carlton) 15(8):725\u2013731. https:\/\/doi.org\/10.1111\/j.1440-1797.2010.01432.x","journal-title":"Nephrology (Carlton)"},{"key":"4149_CR60","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","volume":"15","author":"R Kemp","year":"2017","unstructured":"Kemp R, Prasad V (2017) Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 15:134. https:\/\/doi.org\/10.1186\/s12916-017-0902-9","journal-title":"BMC Med"},{"issue":"1","key":"4149_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00228-023-03582-5","volume":"80","author":"S Khiali","year":"2024","unstructured":"Khiali S, Taban-Sadeghi M, Sarbakhsh P, Khezerlouy-Aghdam N, Entezari-Maleki T (2024) Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial. Eur J Clin Pharmacol 80(1):93\u2013104. https:\/\/doi.org\/10.1007\/s00228-023-03582-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"4149_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/medicines12010005","volume":"12","author":"NN Knezevic","year":"2025","unstructured":"Knezevic NN, Sic A, Worobey S, Knezevic E (2025) Justice for placebo: placebo effect in clinical trials and everyday practice. Medicines 12(1):5. https:\/\/doi.org\/10.3390\/medicines12010005","journal-title":"Medicines"},{"key":"4149_CR63","doi-asserted-by":"publisher","unstructured":"Kostis JB, Dobrzynski JM (2020) Limitations of randomized clinical trials. Am J Cardiol 129:109\u2013115. https:\/\/doi.org\/10.1016\/j.amjcard.2020.05.011","DOI":"10.1016\/j.amjcard.2020.05.011"},{"issue":"2","key":"4149_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1134\/S1068162023020139","volume":"49","author":"VS Kulkarni","year":"2023","unstructured":"Kulkarni VS, Alagarsamy V, Solomon VR, Jose PA, Murugesan S (2023) Drug repurposing: an effective tool in modern drug discovery. Russ J Bioorg Chem 49(2):157\u2013166. https:\/\/doi.org\/10.1134\/S1068162023020139","journal-title":"Russ J Bioorg Chem"},{"issue":"3","key":"4149_CR65","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/CAD.0000000000000464","volume":"28","author":"A Kumar","year":"2017","unstructured":"Kumar A, Sharma PR, Mondhe DM (2017) Potential anticancer role of colchicine-based derivatives: an overview. Anticancer Drugs 28(3):250\u2013262. https:\/\/doi.org\/10.1097\/CAD.0000000000000464","journal-title":"Anticancer Drugs"},{"key":"4149_CR66","doi-asserted-by":"publisher","unstructured":"Leah OM, Lea\u015fu FG, Badea M, Constantinescu M, V\u00e2rciu M, Rogozea LM (2026) Repurposed drugs and cardiovascular morbidity: a cost-effectiveness analysis. Am J Ther, https:\/\/doi.org\/10.1097\/MJT.0000000000002156","DOI":"10.1097\/MJT.0000000000002156"},{"issue":"12","key":"4149_CR67","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10822-021-00430-5","volume":"35","author":"RA Lewis","year":"2021","unstructured":"Lewis RA (2021) Best practices for repurposing studies. J Comput Aided Mol Des 35(12):1189\u20131193. https:\/\/doi.org\/10.1007\/s10822-021-00430-5","journal-title":"J Comput Aided Mol Des"},{"key":"4149_CR68","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R et al (2023) Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov 22:449\u2013475. https:\/\/doi.org\/10.1038\/s41573-023-00672-y","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"4149_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35988","volume":"10","author":"Y Liang","year":"2024","unstructured":"Liang Y, Quan X, Gu R, Meng Z, Gan H, Wu Z, Sun Y, Pan H, Han P, Liu S, Dou G (2024) Repurposing existing drugs for the treatment ofCOVID-19\/SARS-CoV-2: A review of pharmacological effects and mechanism of action. Heliyon 10(16):e35988. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35988","journal-title":"Heliyon"},{"issue":"6","key":"4149_CR70","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2174\/1381612824666180116095658","volume":"24","author":"G Liantinioti","year":"2018","unstructured":"Liantinioti G, Argyris AA, Protogerou AD, Vlachoyiannopoulos P (2018) The role of colchicine in the treatment of autoinflammatory diseases. Curr Pharm Des 24(6):690\u2013694. https:\/\/doi.org\/10.2174\/1381612824666180116095658","journal-title":"Curr Pharm Des"},{"issue":"8","key":"4149_CR71","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/life11080864","volume":"11","author":"CH Lien","year":"2021","unstructured":"Lien CH, Lee MD, Weng SL, Lin CH, Liu LY, Tai YL, Lei WT, Liu JM, Huang YN, Chi H, Chiu NC, Lin CY (2021) Repurposing colchicine in treating patients with COVID-19: a systematic review and meta-analysis. Life (Basel, Switzerland) 11(8):864. https:\/\/doi.org\/10.3390\/life11080864","journal-title":"Life (Basel, Switzerland)"},{"issue":"3","key":"4149_CR72","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4097\/kja.19049","volume":"72","author":"CY Lim","year":"2019","unstructured":"Lim CY, In J (2019) Randomization in clinical studies. Korean J Anesthesiol 72(3):221\u2013232. https:\/\/doi.org\/10.4097\/kja.19049","journal-title":"Korean J Anesthesiol"},{"issue":"20","key":"4149_CR73","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.3390\/cancers15205031","volume":"15","author":"J-J Lin","year":"2023","unstructured":"Lin J-J, Lin C-L, Chen C-C, Lin Y-H, Cho D-Y, Chen X, Chen D-C, Chen H-Y (2023) Unlocking Colchicine\u2019s untapped potential: a paradigm shift in hepatocellular carcinoma prevention. Cancers 15(20):5031. https:\/\/doi.org\/10.3390\/cancers15205031","journal-title":"Cancers"},{"issue":"7","key":"4149_CR74","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/kjm2.12374","volume":"37","author":"ZY Lin","year":"2021","unstructured":"Lin ZY, Yeh ML, Huang CI, Chen SC, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL (2021) Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. Kaohsiung J Med Sci 37(7):616\u2013623. https:\/\/doi.org\/10.1002\/kjm2.12374","journal-title":"Kaohsiung J Med Sci"},{"issue":"4","key":"4149_CR75","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/rheumatology\/kead625","volume":"63","author":"LK Stamp","year":"2023","unstructured":"Stamp LK, Horsley C, Te Karu L, Dalbeth N, Barclay M (2023) Colchicine: the good, the bad, the ugly and how to minimize the risks. Rheumatology 63(4):936\u2013944. https:\/\/doi.org\/10.1093\/rheumatology\/kead625","journal-title":"Rheumatology"},{"issue":"3","key":"4149_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100159","volume":"2","author":"M Louchet","year":"2020","unstructured":"Louchet M, Sibiude J, Peytavin G, Picone O, Tr\u00e9luyer JM, Mandelbrot L (2020) Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. Am J Obstet Gynecol MFM 2(3):100159. https:\/\/doi.org\/10.1016\/j.ajogmf.2020.100159","journal-title":"Am J Obstet Gynecol MFM"},{"key":"4149_CR77","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1745-6215-13-146","volume":"13","author":"A Lundh","year":"2012","unstructured":"Lundh A, Krogsb\u00f8ll LT, G\u00f8tzsche PC (2012) Sponsors\u2019 participation in conduct and reporting of industry trials: a descriptive study. Trials 13:146. https:\/\/doi.org\/10.1186\/1745-6215-13-146","journal-title":"Trials"},{"issue":"1265","key":"4149_CR78","first-page":"U2808","volume":"120","author":"J Ly","year":"2007","unstructured":"Ly J, Gow P, Dalbeth N (2007) Colchicine prescribing and safety monitoring in patients with gout. N Z Med J 120(1265):U2808","journal-title":"N Z Med J"},{"key":"4149_CR79","unstructured":"Lynch SS (2025) Adverse Drug Reactions. MSD Manual. Last updated: April 2025. Last accessed: September 05 2025. https:\/\/www.msdmanuals.com\/home\/drugs\/overview-of-medications\/adverse-drug-reactions"},{"issue":"3","key":"4149_CR80","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4103\/CRST.CRST_211_20","volume":"3","author":"JJ Manjali","year":"2020","unstructured":"Manjali JJ, Gupta T (2020) Critical appraisal of a clinical research paper: what one needs to know. Cancer Res Stat Treat 3(3):545\u2013551. https:\/\/doi.org\/10.4103\/CRST.CRST_211_20","journal-title":"Cancer Res Stat Treat"},{"issue":"2","key":"4149_CR81","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/17407745231203391","volume":"21","author":"MJ Martens","year":"2024","unstructured":"Martens MJ, Logan BR (2024) Statistical rules for safety monitoring in clinical trials. Clinical trials (London, England) 21(2):152\u2013161. https:\/\/doi.org\/10.1177\/17407745231203391","journal-title":"Clinical trials (London, England)"},{"key":"4149_CR82","doi-asserted-by":"publisher","unstructured":"Mashayekhi NR, Alisaeedi A, Rostami A, Soltani P (2020) The impact of colchicine in preventing postpericardiotomy syndrome; a double-blind clinical trial study. Immunopathol. Persa 6(1):e11. https:\/\/doi.org\/10.15171\/ipp.2020.11","DOI":"10.15171\/ipp.2020.11"},{"issue":"12","key":"4149_CR83","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.1111\/dom.70139","volume":"27","author":"DS Mathiesen","year":"2025","unstructured":"Mathiesen DS, Hansen JV, H\u00f8ck A, Nielsen CK, Pedersen MG, Kristensen PL, Andersen HU, Aarestrup ML, Forman JL, Bagger JI, Dejgaard TF, Knop FK, Johansen NJ, Lund AB (2025) Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: design and rationale of the REC1TE trial. Diabetes Obes Metab 27(12):6884\u20136893. https:\/\/doi.org\/10.1111\/dom.70139","journal-title":"Diabetes Obes Metab"},{"key":"4149_CR84","unstructured":"Matthew JP, Higgins JP, Sterne JA (2025) Cochrane Handbook for Systematic Reviews of Interventions. Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis. Cochrane Collaboration, London. Last updated: 2025. Last accessed: August 31 2025. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-13"},{"issue":"1","key":"4149_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152437","volume":"53","author":"S Matza Porges","year":"2026","unstructured":"Matza Porges S, Shamriz O, Ben-Sasson SZ (2026) Colchicine as an anti-inflammatory agent improving cancer prognosis: a therapeutic repurposing perspective. Semin Oncol 53(1):152437. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152437","journal-title":"Semin Oncol"},{"issue":"11","key":"4149_CR86","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00296-020-04694-2","volume":"40","author":"DP Misra","year":"2020","unstructured":"Misra DP, Gasparyan AY, Zimba O (2020) Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. Rheumatol Int 40(11):1741\u20131751. https:\/\/doi.org\/10.1007\/s00296-020-04694-2","journal-title":"Rheumatol Int"},{"key":"4149_CR87","doi-asserted-by":"publisher","unstructured":"Mohammad A, Mascarenhas J, Marcellino BK, Nathan DI (2025) Target practice: opportunities for therapeutic intervention in CHIP and CCUS. Blood Rev 101323. https:\/\/doi.org\/10.1016\/j.blre.2025.101323","DOI":"10.1016\/j.blre.2025.101323"},{"key":"4149_CR88","doi-asserted-by":"publisher","unstructured":"Moka MK, George M, Rathakrishnan D, Jagadeeshwaran V, DK S (2025) Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations. Curr Res Transl Med 73(2):103496. https:\/\/doi.org\/10.1016\/j.retram.2025.103496","DOI":"10.1016\/j.retram.2025.103496"},{"issue":"2","key":"4149_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2025.103496","volume":"73","author":"MK Moka","year":"2025","unstructured":"Moka MK, George M, Rathakrishnan D, Jagadeeshwaran V, D K S (2025) Trends in drug repurposing: advancing cardiovascular disease management in geriatric populations. Curr Res Transl Med 73(2):103496. https:\/\/doi.org\/10.1016\/j.retram.2025.103496","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"4149_CR90","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10557-020-07106-6","volume":"36","author":"NJ Montarello","year":"2022","unstructured":"Montarello NJ, Nguyen MT, Wong DTL, Nicholls SJ, Psaltis PJ (2022) Inflammation in coronary atherosclerosis and its therapeutic implications. Cardiovasc Drugs Ther 36(2):347\u2013362. https:\/\/doi.org\/10.1007\/s10557-020-07106-6","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"4149_CR91","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.clinthera.2021.11.019","volume":"44","author":"RL Morrow","year":"2022","unstructured":"Morrow RL, Mintzes B, Gray G, Law MR, Garrison S, Dormuth CR (2022) Industry sponsor influence in clinical trial reporting in Canada: a qualitative interview study. Clin Ther 44(3):374\u2013388. https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.019","journal-title":"Clin Ther"},{"key":"4149_CR92","unstructured":"National Library of Medicine (NLM). (2025). ClinicalTrials.gov. Last updated: 2025. Last accessed: September 09 2025. https:\/\/clinicaltrials.gov\/"},{"issue":"11","key":"4149_CR93","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.clinthera.2023.07.007","volume":"45","author":"SM Nidorf","year":"2023","unstructured":"Nidorf SM (2023) Seeing colchicine in a new light: repurposing low-dose colchicine for secondary prevention of cardiovascular disease. Clin Ther 45(11):1029\u20131033. https:\/\/doi.org\/10.1016\/j.clinthera.2023.07.007","journal-title":"Clin Ther"},{"issue":"7","key":"4149_CR94","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","volume":"82","author":"K Nelson","year":"2023","unstructured":"Nelson K, Fuster V, Ridker PM (2023) Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J Am Coll Cardiol 82(7):648\u2013660. https:\/\/doi.org\/10.1016\/j.jacc.2023.05.055","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"4149_CR95","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61(4):404\u2013410. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.027","journal-title":"J Am Coll Cardiol"},{"key":"4149_CR96","doi-asserted-by":"publisher","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, \u2026 LoDoCo2 Trial Investigators (2020). Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 383(19):1838\u20131847. https:\/\/doi.org\/10.1056\/NEJMoa2021372","DOI":"10.1056\/NEJMoa2021372"},{"issue":"Suppl 4","key":"4149_CR97","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.5005\/jp-journals-10071-23638","volume":"24","author":"BD Nimavat","year":"2020","unstructured":"Nimavat BD, Zirpe KG, Gurav SK (2020) Critical Analysis of a randomized controlled trial. Indian J Crit Care Med 24(Suppl 4):S215\u2013S222. https:\/\/doi.org\/10.5005\/jp-journals-10071-23638","journal-title":"Indian J Crit Care Med"},{"key":"4149_CR98","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13054-023-04341-9","volume":"27","author":"T Pan","year":"2023","unstructured":"Pan T, Jiang CY, Zhang H et al (2023) The low-dose colchicine in patients after non-CABG cardiac surgery: a randomized controlled trial. Crit Care 27:49. https:\/\/doi.org\/10.1186\/s13054-023-04341-9","journal-title":"Crit Care"},{"key":"4149_CR99","doi-asserted-by":"publisher","unstructured":"Pinzi L, Bisi N, Rastelli G (2024) How drug repurposing can advance drug discovery: challenges and opportunities. Front Drug Discov 4. https:\/\/doi.org\/10.3389\/fddsv.2024.1460100","DOI":"10.3389\/fddsv.2024.1460100"},{"issue":"12","key":"4149_CR100","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/ATVBAHA.124.319980","volume":"44","author":"N Potere","year":"2024","unstructured":"Potere N, Bonaventura A, Abbate A (2024) Novel Therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases. Arterioscler Thromb Vasc Biol 44(12):2371\u20132395. https:\/\/doi.org\/10.1161\/ATVBAHA.124.319980","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4149_CR101","doi-asserted-by":"publisher","unstructured":"Psaltis PJ, Nguyen MT, Singh K, Sinhal A, Wong DTL, Alcock R, Rajendran S, Dautov R, Barlis P, Patel S, Salagaras T, Marathe JA, Bursill CA, Montarello NJ, Nidorf SM, Thompson PL, Butters J, Cuthbert AR, Yelland LN, Ottaway JL, \u2026 Nicholls SJ (2025) Optical coherence tomography assessment of the impact of colchicine on non-culprit coronary plaque composition after myocardial infarction. Cardiovasc Res 121(3):468\u2013478. https:\/\/doi.org\/10.1093\/cvr\/cvae191","DOI":"10.1093\/cvr\/cvae191"},{"key":"4149_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.876718","volume":"9","author":"A Rabbani","year":"2022","unstructured":"Rabbani A, Rafique A, Wang X, Campbell D, Wang D, Brownell N, Capdevilla K, Garabedian V, Chaparro S, Herrera R, Parikh RV, Ardehali R (2022) Colchicine for the treatment of cardiac injury in hospitalized patients with coronavirus disease-19. Front Cardiovasc Med 9:876718. https:\/\/doi.org\/10.3389\/fcvm.2022.876718","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"4149_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00733-3","volume":"20","author":"SR Raeeskarami","year":"2022","unstructured":"Raeeskarami SR, Sadeghi P, Vahedi M, Asna Ashari K, Mousavi T M, Ziaee V (2022) Colchicine versus cimetidine: the better choice for Periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome prophylaxis, and the role of MEFV gene mutations. Pediatr Rheumatol 20(1):72. https:\/\/doi.org\/10.1186\/s12969-022-00733-3","journal-title":"Pediatr Rheumatol"},{"key":"4149_CR104","doi-asserted-by":"publisher","unstructured":"Rietdik WJ, Dr\u00e4ger S (2024). What every intensivist should know about: the value of limitations in clinical research. J Crit Care 83:154457. https:\/\/doi.org\/10.1016\/j.jcrc.2023.154457","DOI":"10.1016\/j.jcrc.2023.154457"},{"issue":"11","key":"4149_CR105","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400492","volume":"357","author":"JS Rodr\u00edguez-Zavala","year":"2024","unstructured":"Rodr\u00edguez-Zavala JS, Zazueta C (2024) Novel drug design and repurposing: an opportunity to improve translational research in cardiovascular diseases? Arch Pharm (Weinheim) 357(11):e2400492. https:\/\/doi.org\/10.1002\/ardp.202400492","journal-title":"Arch Pharm (Weinheim)"},{"key":"4149_CR106","doi-asserted-by":"publisher","unstructured":"Roubille F, Bouabdallaoui N, Kouz S, Waters DD, Diaz R, Maggioni AP, Pinto FJ, Gr\u00e9goire JC, Gamra H, Kiwan GS, Berry C, L\u00f3pez-Send\u00f3n J, Koenig W, Delorme L, Elbaz M, Coste P, Provencher M, Bassevitch Z, Blondeau L, L\u2019Allier PL, \u2026 Tardif JC (2024) Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Diab Care 47(3):467\u2013470. https:\/\/doi.org\/10.2337\/dc23-1825","DOI":"10.2337\/dc23-1825"},{"key":"4149_CR107","doi-asserted-by":"publisher","unstructured":"Rudi J, Raedsch R, Gerteis C, Schlenker T, Plachky J, Walter-Sack I, \u2026 Kommerell B (1994) Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. Scand J Gastroenterol 29(4):346\u2013351. https:\/\/doi.org\/10.3109\/00365529409094847","DOI":"10.3109\/00365529409094847"},{"key":"4149_CR108","doi-asserted-by":"publisher","unstructured":"Salehzadeh F, Pourfarzi F, Ataei S (2022) The Impact of colchicine on COVID-19 patients: a clinical trial study. Mediterr. J. Rheumatol 33(2):232\u2013236. https:\/\/doi.org\/10.31138\/mjr.33.2.232","DOI":"10.31138\/mjr.33.2.232"},{"issue":"5","key":"4149_CR109","doi-asserted-by":"publisher","first-page":"693","DOI":"10.4103\/idoj.IDOJ_475_20","volume":"11","author":"K Sardana","year":"2020","unstructured":"Sardana K, Sinha S, Sachdeva S (2020) Colchicine in dermatology: rediscovering an old drug with novel uses. Indian Dermatol Online J 11(5):693\u2013700. https:\/\/doi.org\/10.4103\/idoj.IDOJ_475_20","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"4149_CR110","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s10753-015-0237-7","volume":"39","author":"B Shah","year":"2016","unstructured":"Shah B, Allen N, Harchandani B, Pillinger M, Katz S, Sedlis SP, Echagarruga C, Samuels SK, Morina P, Singh P, Karotkin L, Berger JS (2016) Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects. Inflammation 39(1):182\u2013189. https:\/\/doi.org\/10.1007\/s10753-015-0237-7","journal-title":"Inflammation"},{"issue":"4","key":"4149_CR111","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","volume":"13","author":"B Shah","year":"2020","unstructured":"Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, Smilowitz NR, Feit F, Ratnapala N, Keller NM, Katz SD (2020) Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv 13(4):e008717. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008717","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"4149_CR112","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40744-025-00772-8","volume":"12","author":"J Shah","year":"2025","unstructured":"Shah J, Pillinger MH, Chan EK, Lissin D (2025) Prophylaxis of gout flares in patients with renal impairment: dosing adjustments with colchicine oral solution informed by a pharmacokinetic model. Rheumatol Ther 12(4):721\u2013730. https:\/\/doi.org\/10.1007\/s40744-025-00772-8","journal-title":"Rheumatol Ther"},{"key":"4149_CR113","doi-asserted-by":"publisher","unstructured":"Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Huang H, Ul Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, \u2026 Lansky A (2023) Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open 13(2): e067910. https:\/\/doi.org\/10.1136\/bmjopen-2022-067910","DOI":"10.1136\/bmjopen-2022-067910"},{"key":"4149_CR114","doi-asserted-by":"publisher","first-page":"1702293","DOI":"10.3389\/fmed.2025.1702293","volume":"12","author":"M Shi","year":"2026","unstructured":"Shi M, Zhang X, Li L, Wang Y, Zhao Q, Zhen Y, Huang Y, Liu C (2026) Colchicine reduces inflammatory cytokines and improves symptoms in HFpEF: an observational pilot study. Front Med 12:1702293. https:\/\/doi.org\/10.3389\/fmed.2025.1702293","journal-title":"Front Med"},{"key":"4149_CR115","doi-asserted-by":"publisher","unstructured":"Showell MG, Cole S, Clarke MJ, DeVito NJ, Farquhar C, Jordan V (2024) Time to publication for results of clinical trials. Cochrane Database Syst. Rev 11(11). https:\/\/doi.org\/10.1002\/14651858.MR000011.pub3","DOI":"10.1002\/14651858.MR000011.pub3"},{"issue":"3","key":"4149_CR116","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1524-6175.2002.01094.x","volume":"4","author":"DA Sica","year":"2002","unstructured":"Sica DA (2002) Premature termination of clinical trials--lessons learned. J Clin Hypertens (Greenwich) 4(3):219\u2013225. https:\/\/doi.org\/10.1111\/j.1524-6175.2002.01094.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"4149_CR117","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1745-6215-13-138","volume":"13","author":"S Singh","year":"2012","unstructured":"Singh S, Loke YK (2012) Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 13:138. https:\/\/doi.org\/10.1186\/1745-6215-13-138","journal-title":"Trials"},{"key":"4149_CR118","unstructured":"Skelly CL, McMahon K, Munakomi S (2025) Adverse Events. StatPearlsPublishing. Treasure Island (FL). Last updated: August 02 2025. Last accessed: September 09 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558963\/"},{"key":"4149_CR119","doi-asserted-by":"publisher","unstructured":"Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC (2020) Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 22(1):28. https:\/\/doi.org\/10.1186\/s13075-020-2120-7","DOI":"10.1186\/s13075-020-2120-7"},{"issue":"1","key":"4149_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70081","volume":"28","author":"ST Su","year":"2025","unstructured":"Su ST, Lee YH, Wei JC (2025) Colchicine in cardiovascular disease: mechanisms of action and therapeutic potential. Int J Rheum Dis 28(1):e70081. https:\/\/doi.org\/10.1111\/1756-185X.70081","journal-title":"Int J Rheum Dis"},{"key":"4149_CR121","doi-asserted-by":"publisher","unstructured":"Sun D, Gao W, Hu H, Zhou S (2022) Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B 12(7):3049\u20133062. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.002","DOI":"10.1016\/j.apsb.2022.02.002"},{"issue":"5","key":"4149_CR122","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s12055-022-01401-7","volume":"38","author":"V Sundaram","year":"2022","unstructured":"Sundaram V, Selvaganesan P, Deo S, Karnib M (2022) The importance of randomization in clinical research. Indian J Thorac Cardiovasc Surg 38(5):562\u2013565. https:\/\/doi.org\/10.1007\/s12055-022-01401-7","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"4149_CR123","doi-asserted-by":"publisher","unstructured":"Taban-Sadeghi M, Khiali S, Karimi M, Shahidi M, Khani E, Mousavi Z, Entezari-Maleki T (2025) Effects of colchicine on depression scale scores of patients with chronic heart failure with reduced ejection fraction: a randomized clinical trial. J Cardiovasc Thorac Res 17(3), 206\u2013211. https:\/\/doi.org\/10.34172\/jcvtr.025.33169","DOI":"10.34172\/jcvtr.025.33169"},{"key":"4149_CR124","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ahj.2016.05.006","volume":"178","author":"RA Tabbalat","year":"2016","unstructured":"Tabbalat RA, Hamad NM, Alhaddad IA, Hammoudeh A, Akasheh BF, Khader Y (2016) Effect of colchicine on the incidence of atrial fibrillation in open heart surgery patients: END-AF trial. Am Heart J 178:102\u2013107. https:\/\/doi.org\/10.1016\/j.ahj.2016.05.006","journal-title":"Am Heart J"},{"key":"4149_CR125","doi-asserted-by":"publisher","unstructured":"Tardif JC, Bouabdallaoui N, L\u2019Allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, Pelletier M, Tessier PA, Samson S, Fortin D, Tardif JD, Busseuil D, Goulet E, Lacoste C, \u2026 COLCORONA Investigators (2021). Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 9(8):924\u2013932. https:\/\/doi.org\/10.1016\/S2213-2600(21)00222-8","DOI":"10.1016\/S2213-2600(21)00222-8"},{"key":"4149_CR126","doi-asserted-by":"publisher","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, L\u00f3pez-Send\u00f3n J, Ostadal P, Koenig W, Angoulvant D, Gr\u00e9goire JC, Lavoie MA, Dub\u00e9 MP, Rhainds D, Provencher M, \u2026 Roubille F (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381(26): 2497\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1912388","DOI":"10.1056\/NEJMoa1912388"},{"issue":"6","key":"4149_CR127","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jjcc.2020.11.010","volume":"77","author":"YY Tien","year":"2021","unstructured":"Tien YY, Huang HK, Shih MC, Tu YK (2021) Drug repurposing? Cardiovascular effect of colchicine on patients with coronary artery disease: a systematic review and meta-analysis. J Cardiol 77(6):576\u2013582. https:\/\/doi.org\/10.1016\/j.jjcc.2020.11.010","journal-title":"J Cardiol"},{"key":"4149_CR128","doi-asserted-by":"publisher","unstructured":"Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W, Stub D, van Gaal W, Howes L, Collins N, Yong A, Bhindi R, Whitbourn R, Lee A, Hengel C, Asrress K, Freeman M, \u2026 Layland J (2020) Colchicine in patients with acute coronary syndrome: the australian cops randomized clinical trial. Circulation 142(20):1890\u20131900. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050771","DOI":"10.1161\/CIRCULATIONAHA.120.050771"},{"issue":"7","key":"4149_CR129","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Straus SE (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"4149_CR130","doi-asserted-by":"publisher","unstructured":"Trube J, Sabina M, Khanani A, Hernandez K, Khan Z, Bizanti A (2025) Colchicine therapy in cardiovascular medicine: a literature review. Am Heart J Plus: Cardiol Res Pract 52:100525. https:\/\/doi.org\/10.1016\/j.ahjo.2025.100525","DOI":"10.1016\/j.ahjo.2025.100525"},{"key":"4149_CR131","unstructured":"U.S. Food and Drug Administration (FDA) (2025) For healthcare professionals. FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems. Drug Interactions & Labeling. Last updated: June 27 2025. Last accessed: September 05 2025. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems"},{"issue":"1","key":"4149_CR132","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018993","volume":"10","author":"K Vaidya","year":"2021","unstructured":"Vaidya K, Tucker B, Kurup R, Khandkar C, Pandzic E, Barraclough J, Machet J, Misra A, Kavurma M, Martinez G, Rye KA, Cochran BJ, Patel S (2021) Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention. J Am Heart Assoc 10(1):e018993. https:\/\/doi.org\/10.1161\/JAHA.120.018993","journal-title":"J Am Heart Assoc"},{"key":"4149_CR133","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40258-023-00816-6","volume":"21","author":"KH van der Pol","year":"2023","unstructured":"van der Pol KH, Aljofan M, Blin O et al (2023) Drug repurposing of generic drugs: challenges and the potential role for government. Appl Health Econ Health Policy 21:831\u2013840. https:\/\/doi.org\/10.1007\/s40258-023-00816-6","journal-title":"Appl Health Econ Health Policy"},{"key":"4149_CR134","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/d41586-023-02299-w","volume":"619","author":"R Van Noorden","year":"2023","unstructured":"Van Noorden R (2023) Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature 619:454\u2013458. https:\/\/doi.org\/10.1038\/d41586-023-02299-w","journal-title":"Nature"},{"issue":"6","key":"4149_CR135","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-023-03486-4","volume":"79","author":"ES Vaz","year":"2023","unstructured":"Vaz ES, Vassiliades SV, Giarolla J, Polli MC, Parise-Filho R (2023) Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. Eur J Clin Pharmacol 79(6):723\u2013751. https:\/\/doi.org\/10.1007\/s00228-023-03486-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4149_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27373","volume":"10","author":"S Vaziri","year":"2024","unstructured":"Vaziri S, Janbakhsh A, Zamanian MH, Shakiba Y, Mostafaei S, Norooznezhad AH, Mansouri K, Bagheri A, Abdali F, Fatahpour K, Mostafaie A (2024) Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential treatment for patients diagnosed with COVID-19: a randomized controlled parallel clinical trial. Heliyon 10(6):e27373. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27373","journal-title":"Heliyon"},{"key":"4149_CR137","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2288-5-26","volume":"5","author":"H Walach","year":"2005","unstructured":"Walach H, Sadaghiani C, Dehm C, Bierman D (2005) The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials\u2013a secondary analysis. BMC Med Res Methodol 5:26. https:\/\/doi.org\/10.1186\/1471-2288-5-26","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"4149_CR138","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/pm\/pnac040","volume":"23","author":"WS Warner","year":"2022","unstructured":"Warner WS, Mahan MA (2022) What is a high-quality randomized controlled trial? Pain Med (Malden, Mass) 23(4):607\u2013609. https:\/\/doi.org\/10.1093\/pm\/pnac040","journal-title":"Pain Med (Malden, Mass)"},{"key":"4149_CR139","doi-asserted-by":"crossref","unstructured":"Williams RJ, Tse T, DiPiazza K, Zarin DA (2015) Terminated trials in the Clinicaltrials.gov results database: evaluation of availability of primary outcome data and reasons for termination. PloS One 10(5):e0127242. 10.1371\/journal.pone.0127242","DOI":"10.1371\/journal.pone.0127242"},{"key":"4149_CR140","unstructured":"World Health Organization (WHO). (2025a). Disease Outbreak News; COVID-19 - Global situation. Last updated: May 28 2025. Last accessed: September 03 2025.\u00a0https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON572"},{"key":"4149_CR141","unstructured":"World Health Organization (WHO). (2025b). Statement on the antigen composition of COVID-19 vaccines. Last updated: May 15 2025. Last accessed: September 03 2025. https:\/\/www.who.int\/news\/item\/15-05-2025-statement-on-the-antigen-composition-of-covid-19-vaccines"},{"key":"4149_CR142","unstructured":"World Health Organization (WHO). (2026). International Clinical Trials Registry Platform (ICTRP). WHO, 2026. Last accessed: July 06 2026. https:\/\/www.who.int\/tools\/clinical-trials-registry-platform"},{"issue":"1","key":"4149_CR143","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/pharmaceutics5010094","volume":"5","author":"B Yao","year":"2013","unstructured":"Yao B, Zhu L, Jiang Q, Xia HA (2013) Safety monitoring in clinical trials. Pharmaceutics 5(1):94\u2013106. https:\/\/doi.org\/10.3390\/pharmaceutics5010094","journal-title":"Pharmaceutics"},{"issue":"4","key":"4149_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266245","volume":"17","author":"F Yasmin","year":"2022","unstructured":"Yasmin F, Najeeb H, Moeed A, Hassan W, Khatri M, Asghar MS, Naveed AK, Ullah W, Surani S (2022) Safety and efficacy of colchicine in COVID-19 patients: a systematic review and meta-analysis of randomized control trials. PLoS ONE 17(4):e0266245. https:\/\/doi.org\/10.1371\/journal.pone.0266245","journal-title":"PLoS ONE"},{"issue":"2","key":"4149_CR145","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/BOR.0000000000000784","volume":"33","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Choi HK, Solomon DH (2021) Medications for gout and its comorbidities: mutual benefits? Curr Opin Rheumatol 33(2):145\u2013154. https:\/\/doi.org\/10.1097\/BOR.0000000000000784","journal-title":"Curr Opin Rheumatol"},{"key":"4149_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114296","volume":"183","author":"H Yousefi","year":"2021","unstructured":"Yousefi H, Mashouri L, Okpechi SC, Alahari N, Alahari SK (2021) Repurposing existing drugs for the treatment of COVID-19\/SARS-CoV-2 infection: a review describing drug mechanisms of action. Biochem Pharmacol 183:114296. https:\/\/doi.org\/10.1016\/j.bcp.2020.114296","journal-title":"Biochem Pharmacol"},{"key":"4149_CR147","doi-asserted-by":"publisher","unstructured":"Yousefzadeh M, Khosrobeigi A, Salehi A (2024) Studying the efficacy of low-dose colchicine on clinical outcomes of patients with STEMI: a randomized controlled trial. Egypt Heart J 76(1): 85. https:\/\/doi.org\/10.1186\/s43044-024-00515-0","DOI":"10.1186\/s43044-024-00515-0"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04149-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04149-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04149-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:33Z","timestamp":1789454853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04149-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":147,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4149"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04149-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School (\n                      \n                      . The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable because publicly available information is used as a data source.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"238"}}